Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122843 · ClinicalTrials.gov registry record · NA
VR AI Meditation for Pain
A NA study of Pain and Anxiety, sponsored by Christopher Almario.
- Recruiting
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT07122843: Recruiting NA study of Pain and Anxiety, sponsored by Christopher Almario.
NCT07122843 is a NA study of Pain and Anxiety that is actively recruiting participants, run by Christopher Almario. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07122843, a NA study of Pain and Anxiety, is actively recruiting participants, sponsored by Christopher Almario.
- RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to assess changes in pain and anxiety as reported by the Pain Numeric Rating Scale (PNRS) and the State-Trait Anxiety Inventory 6 (STAI-6), pre and post a guided meditation in Virtual reality. Objectives of the study are also to determine the feasibility, and patient acceptance of utilizing a LLM-generated guided meditation in VR. Our goal is to learn about any limitations of our approach and provide a pathway for future improvements in creating a VR AI therapist that is optimally aligned with the needs of users.
Primary Outcome
To evaluate impact to pain levels after VR guided meditation (1 time). We will use a validated pain survey and look at Pain Numeric Rating Scale (pre compared to post-VR).
Conditions Studied
Interventions
- DEVICE VR Guided Meditation
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2027-01-20 |
| Phase | NA |
What NCT07122843 shows while recruiting
NCT07122843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Pain and Anxiety appearing as the primary indexed condition, and to 1 intervention - of which VR Guided Meditation is the first listed.
NCT07122843 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07122843 about?
NCT07122843 is a clinical study titled "VR AI Meditation for Pain". This study aims to assess changes in pain and anxiety as reported by the Pain Numeric Rating Scale (PNRS) and the State-Trait Anxiety Inventory 6 (STAI-6), pre and post a guided meditation in Virtual reality. Objectives of the study are also to determine the feasibility, and patient acceptance of ut...
What is the current status of trial NCT07122843?
This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2025-11-06. Estimated completion is 2027-01-20.
What conditions does trial NCT07122843 study?
This clinical trial studies the following conditions: Pain and Anxiety.
What interventions are being tested in trial NCT07122843?
The interventions under investigation include: VR Guided Meditation (DEVICE).
Who is sponsoring clinical trial NCT07122843?
This trial is sponsored by Christopher Almario, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122843 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07122843's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI